Back to funds
View filing
Vivo Capital, LLC
hedge fundUpdated 28 days agoManaged by Vivo Capital, Llc • Latest filing Q2 2026
Portfolio value
$1.1B
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
2.6%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $1.4B |
| Q2 2023 | $1.4B |
| Q3 2023 | $912.8M |
| Q4 2023 | $1.2B |
| Q1 2024 | $1.3B |
| Q2 2024 | $1.1B |
| Q3 2024 | $1.2B |
| Q4 2024 | $892.6M |
| Q1 2025 | $755.1M |
| Q2 2025 | $977.1M |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.5B |
| Q1 2026 | $1.2B |
| Q2 2026 | $1.1B |
Top holdings
47 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | T TRVI Trevi Therapeutics Inc | $95M | 5.09M | 8.68% | — |
| 2 | P PRAX Praxis Precision Medicines | $90.8M | 271.1K | 8.29% | — |
| 3 | E EQR Erasca Inc | $75.6M | 4.13M | 6.90% | — |
| 4 | ? N/A Arrivent BioPharma Inc | $58.4M | 1.68M | 5.34% | — |
| 5 | A AAVXF Abivax SA - ADR | $55.3M | 414.9K | 5.05% | — |
| 6 | T TNGX Tango Therapeutics Inc | $43.1M | 1.38M | 3.94% | — |
| 7 | C CRVS Corvus Pharmaceuticals Inc | $41.9M | 2.81M | 3.83% | — |
| 8 | D DRUG Bright Minds Biosciences Inc | $39.1M | 557.2K | 3.57% | — |
| 9 | S SVA Sinovac Biotech Ltd. | $38.2M | 5.90M | 3.49% | — |
| 10 | ? N/A Tenax Therapeutics Inc | $36.4M | 2.50M | 3.32% | — |
| 11 | A ACRS Aclaris Therapeutics, Inc. | $35.4M | 6.69M | 3.23% | — |
| 12 | D DYN Dyne Therapeutics Inc | $34.6M | 1.56M | 3.16% | — |
| 13 | D DNTH Dianthus Therapeutics Inc | $34.5M | 354.0K | 3.15% | — |
| 14 | A ANRO Alto Neuroscience Inc | $31.9M | 1.21M | 2.91% | — |
| 15 | D DBVTF DBV Technologies SA | $30.3M | 1.84M | 2.76% | — |
| 16 | S SABSW SAB Biotherapeutics Inc | $28.5M | 7.30M | 2.60% | — |
| 17 | M MLTX Moonlake Immunotherapeutics | $27.3M | 1.40M | 2.49% | — |
| 18 | L LBRX LB Pharmaceuticals Inc | $26M | 800.0K | 2.37% | — |
| 19 | N NERV Minerva Neurosciences Inc | $24M | 4.32M | 2.19% | — |
| 20 | D DSGN Design Therapeutics Inc | $23.3M | 1.61M | 2.13% | — |